Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 88.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,803 shares of the company’s stock after selling 219,621 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Neurocrine Biosciences were worth $3,434,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NBIX. RFP Financial Group LLC raised its holdings in Neurocrine Biosciences by 346.5% during the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after purchasing an additional 149 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Neurocrine Biosciences in the second quarter valued at approximately $28,000. Innealta Capital LLC purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $30,000. New Covenant Trust Company N.A. acquired a new position in shares of Neurocrine Biosciences during the 1st quarter worth approximately $32,000. Finally, EdgeRock Capital LLC acquired a new position in shares of Neurocrine Biosciences in the second quarter worth $35,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on NBIX. Barclays reduced their target price on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Robert W. Baird increased their price target on Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Guggenheim raised their price objective on Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Oppenheimer raised their price target on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $163.91.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total transaction of $40,322.10. Following the sale, the insider now directly owns 6,607 shares of the company’s stock, valued at approximately $975,853.90. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 273 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $147.70, for a total transaction of $40,322.10. Following the transaction, the insider now directly owns 6,607 shares in the company, valued at $975,853.90. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gary A. Lyons sold 11,570 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.43, for a total transaction of $1,740,475.10. Following the completion of the sale, the director now directly owns 119,047 shares of the company’s stock, valued at $17,908,240.21. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 47,336 shares of company stock valued at $7,063,652 in the last ninety days. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $124.33 on Thursday. Neurocrine Biosciences, Inc. has a one year low of $103.63 and a one year high of $157.98. The stock’s 50 day moving average price is $121.02 and its 200 day moving average price is $133.65. The firm has a market capitalization of $12.55 billion, a PE ratio of 37.56 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The firm had revenue of $590.20 million for the quarter, compared to analyst estimates of $545.98 million. During the same period in the previous year, the business posted $0.95 earnings per share. Neurocrine Biosciences’s revenue for the quarter was up 30.4% on a year-over-year basis. On average, analysts forecast that Neurocrine Biosciences, Inc. will post 4.37 earnings per share for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.